Centessa Pharmaceuticals plc
CNTA
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which iā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$39.59
Price-0.05%
-$0.02
1Y
Price
Market Cap
$5.908b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$15m
-
1y CAGR-33.3%
3y CAGR-25.0%
5y CAGREarnings
-$197.532m
+16.2%
1y CAGR-3.2%
3y CAGR+8.4%
5y CAGREPS
-$1.46
+29.1%
1y CAGR+10.0%
3y CAGR+18.9%
5y CAGRBook Value
$526.863m
$687.495m
Assets$160.632m
Liabilities$7.573m
DebtDebt to Assets
1.1%
-
Debt to EBITDAFree Cash Flow
-$194.188m
-36.7%
1y CAGR-1.6%
3y CAGR-13.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company